A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

1,118

Participants

Timeline

Start Date

July 24, 2024

Primary Completion Date

August 26, 2025

Study Completion Date

January 7, 2027

Conditions
Neovascular Age-Related Macular DegenerationDiabetic Macular Edema
Interventions
DRUG

Aflibercept 8 mg

Administered by intravitreal (IVT) injection

Trial Locations (54)

11590

Vitreoretinal Consultants of NY - Westbury, Westbury

15143

Sewickley Eye Group, Sewickley

18017

Mid Atlantic Retina, Bethlehem

21740

Cumberland Valley Retina Consultants-Ophthalmology, Hagerstown

Mid Atlantic Retina Specialists Hagerstown, Hagerstown

27587

North Carolina Retina Associates, Wake Forest

29169

Palmetto Retina Center, West Columbia

29456

Charleston Neuroscience Institute LLC, Ladson

30060

Georgia Retina, Marietta

32216

Florida Retina Institute - Jacksonville, Jacksonville

32503

Retina Speciality Institute - Pensacola, Florida, Pensacola

32806

Florida Retina Institute - Orlando, Orlando

33064

Advanced Research, LLC, Deerfield Beach

33617

Retina Vitreous Associates of Florida, Tampa

33711

Retina Vitreous Associates of Florida Saint Petersburg, St. Petersburg

33782

Eye Associates of Pinellas, Pinellas Park

33805

Florida Retina Consultants, Lakeland

33880

Center for Retina and Macular Disease, Winter Haven

37203

Tennessee Retina, PC, Nashville

38671

Deep Blue Retina Clinical Research PLLC, Southaven

44122

Retina Associates of Cleveland - Beachwood, Beachwood

45242

Cincinnati Eye Institute, Cincinnati

55435

Retina Consultants of Minnesota, Edina

60304

Illinois Retina Associates, Oak Park

60439

University Retina and Macula Associates PC - Lemont, Lemont

74114

Tulsa Retina Consultants, Tulsa

75231

Texas Retina Associates - Dallas, Dallas

77384

Retina Consultants Texas, The Woodlands

77401

Retina Consultants of Texas - Houston, Bellaire

77494

Retina Consultants of Texas, Katy

77707

Retina Consultants of Texas, Beaumont

78240

Retina Consultants of Texas, San Antonio

78251

Retina Consultants of Texas Brown Retina Institute, San Antonio

78681

Austin Retina Associates, Round Rock

78705

Austin Retina Associates, Austin

79606

Retina Research Institute of Texas, Abilene

79902

Southwest Retina Consultants, El Paso

80503

Eye care Center of Northern Colorado doing business as Advanced Vision Research Institute, Longmont

80909

Retina Consultants of Southern Colorado, Colorado Springs

87109

Vision Research Center Eye Associates of New Mexico, Albuquerque

90212

Retina Specialists of Beverly Hills, Beverly Hills

90807

South Coast Retina Center, Long Beach

91006

Win Retina - Arcadia, Arcadia

91107

California Eye Specialists Medical Group, Inc., Pasadena

92374

Retina Consultants of Southern California, Redlands

92647

Salehi Retina Institute dba Retina Associates of Southern California, Huntington Beach

93309

California Retina Consultants, Bakersfield

95825

Vrmg Inc, Sacramento

96701

Retina Consultants of Hawaii, Inc., ‘Aiea

97225

EyeHealth Northwest, Portland

98004

Pacific Northwest Retina, Bellevue

06385

Retina Group of New England, Waterford

02114

Opthalmic Consultants of Boston, Boston

00612

Emanuelli Research and Development Center, Arecibo

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06491914 - A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter